Amer Issa, MD
Endocrinology, Diabetes & Metabolism · Saginaw, MINPI 1326302712
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,999 of the $46,943 with a category attached, or 70.3%. Novo Nordisk accounts for 81.4% of it on its own, with 37 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $65.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$38K
- Lilly USA, LLC$970
- Corcept Therapeutics$968
- Tandem Diabetes Care, Inc.$746
- Sanofi-aventis U.S. LLC$648
- Boehringer Ingelheim$559
- plus $5K from 32 others
What the payments were for
- Speaking & faculty fees$32,99970%
- Travel & lodging$2,0274%
- Food & beverage$11,89425%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 228 | $38,199 |
| Lilly USA, LLC | 67 | $970 |
| Corcept Therapeutics | 61 | $968 |
| Tandem Diabetes Care, Inc. | 44 | $746 |
| Sanofi-aventis U.S. LLC | 33 | $648 |
| Boehringer Ingelheim | 30 | $559 |
| AstraZeneca(2 entities) | 26 | $539 |
| Amgen(2 entities) | 27 | $524 |
| Medtronic(2 entities) | 25 | $464 |
| Insulet Corporation | 24 | $434 |
| Abbott | 22 | $411 |
| Dexcom, Inc. | 21 | $381 |
| Xeris Pharmaceuticals, Inc. | 18 | $322 |
| AbbVie | 17 | $317 |
| Radius Health, Inc. | 12 | $218 |
| Antares Pharma, Inc. | 11 | $198 |
| Bayer | 8 | $156 |
| Ascendis Pharma Endocrinology Inc | 5 | $112 |
| BETA Bionics, Inc. | 4 | $110 |
| IBSA Pharma Inc. | 6 | $93 |
| Recordati_rare_diseases_inc. | 4 | $82 |
| Ultragenyx Pharmaceutical Inc. | 2 | $66 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| Tolmar, Inc. | 3 | $45 |
| Johnson & Johnson | 3 | $38 |
| Alvogen Inc | 2 | $37 |
| Cequr Corporation | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Pfizer | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Merck | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Companion Medical, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,943 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,156 | $1,604,760 |
| MounjaroTirzepatide | 1,089 | $1,400,324 |
| JardianceEmpagliflozin | 652 | $833,404 |
| RecorlevLevoketoconazole | 12 | $265,528 |
| KorlymMifepristone | 16 | $258,757 |
| TrulicityDulaglutide | 133 | $217,018 |
| FarxigaDapagliflozin Propanediol | 219 | $213,052 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 134 | $167,658 |
| RybelsusSemaglutide | 73 | $153,799 |
| Novolog FlexpenInsulin Aspart | 291 | $86,496 |
| Humalog Kwikpen U-100Insulin Lispro | 249 | $79,108 |
| TymlosAbaloparatide | 29 | $75,701 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $68,978 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 71 | $56,790 |
| GenotropinSomatropin | 12 | $56,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $38,199 | $1,785,2951,373 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $970 | $1,637,2061,317 claims |
| Boehringer IngelheimJardiance | $559 | $833,404652 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $322 | $265,52812 claims |
| Corcept TherapeuticsKorlym | $968 | $258,75716 claims |
| AstraZenecaFarxiga | $539 | $213,052219 claims |
| Radius Health, Inc.Tymlos | $218 | $75,70129 claims |
| PfizerGenotropin | $23 | $56,09412 claims |
| AmgenProlia | $524 | $53,65732 claims |
| Johnson & JohnsonInvokana | $38 | $45,46437 claims |
| MerckJanuvia, Janumet | $18 | $27,94627 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $93 | $14,26740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Saginaw
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.